Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance
T Araki, S Kanda, H Horinouchi… - Japanese Journal of …, 2023 - academic.oup.com
Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated
EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study …
EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study …
Multifactorial diseases of the heart, kidneys, lungs, and liver and incident cancer: epidemiology and shared mechanisms
C Shi, S de Wit, E Učambarlić… - Cancers, 2023 - mdpi.com
Simple Summary Multifactorial diseases are caused by a combination of genetic and
environmental factors and various risk factors that accumulate with age. Cardiovascular …
environmental factors and various risk factors that accumulate with age. Cardiovascular …
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis …
L Zhang, L Wang, J Wang, J Chen, Z Meng, Z Liu… - Molecular Cancer, 2023 - Springer
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
Current status and future of anti-angiogenic drugs in lung cancer
X Yan, Z Zhao, H Tang - Clinical and Experimental Medicine, 2023 - Springer
Lung cancer, as a malignant tumor with both high incidence and mortality in China, is one of
the major causes of death in our population and one of the major public health problems in …
the major causes of death in our population and one of the major public health problems in …
Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer
Lung cancer (LC) is associated with ageing, with the average age of affected individuals
being approximately 70 years. However, despite a higher incidence and prevalence among …
being approximately 70 years. However, despite a higher incidence and prevalence among …
Successful Treatment with Ramucirumab Plus Erlotinib following Osimertinib-induced Interstitial Lung Disease: A Case Report
S Fujimoto, N Katsurada, D Hazama, M Yamamoto… - Internal …, 2024 - jstage.jst.go.jp
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are key drugs for
patients with EGFR mutation-positive non-small-cell lung cancer, and osimertinib is the …
patients with EGFR mutation-positive non-small-cell lung cancer, and osimertinib is the …
[PDF][PDF] Linlin Zhang1, Liuchun Wang2, Jingya Wang2, Jinliang Chen2, Zhaoting Meng2, Zhujun Liu2, Xiangli Jiang2, Xinyue Wang2, Chun Huang2, Peng Chen2, Yan …
Y Shang, Y Zhang, C Zhang, D Huang - 2023 - molecular-cancer.biomedcentral …
Background Non-small cell lung cancer (NSCLC), the leading cause of death (85-90%)
among all malignant lung tumors, is generally related to smoking and more prominent in …
among all malignant lung tumors, is generally related to smoking and more prominent in …